WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
- Published In:
- American journal of hematology, 90(7), 602-7 (2015)
- Authors:
- Brayer, Jason, Lancet, Jeffrey E, Powers, John, List, Alan, Balducci, Lodovico, Komrokji, Rami, Pinilla-Ibarz, Javier
- Database ID:
- RPEP-02590
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02590APA
Brayer, Jason; Lancet, Jeffrey E; Powers, John; List, Alan; Balducci, Lodovico; Komrokji, Rami; Pinilla-Ibarz, Javier. (2015). WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.. American journal of hematology, 90(7), 602-7. https://doi.org/10.1002/ajh.24014
MLA
Brayer, Jason, et al. "WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.." American journal of hematology, 2015. https://doi.org/10.1002/ajh.24014
RethinkPeptides
RethinkPeptides Research Database. "WT1 vaccination in AML and MDS: A pilot trial with synthetic..." RPEP-02590. Retrieved from https://rethinkpeptides.com/research/brayer-2015-wt1-vaccination-in-aml
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.